The Corneal Ulcers drugs in development market research report provides comprehensive information on the therapeutics under development for Corneal Ulcers, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Corneal Ulcers. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Corneal Ulcers and features dormant and discontinued products.
GlobalData tracks seven drugs in development for Corneal Ulcers by seven companies/universities/institutes. The top development phase for Corneal Ulcers is preclinical with two drugs in that stage. The Corneal Ulcers pipeline has six drugs in development by companies and one by universities/ institutes. Some of the companies in the Corneal Ulcers pipeline products market are: University of Dundee, Glaukos and Xequel Bio.
The key targets in the Corneal Ulcers pipeline products market include Ras Related C3 Botulinum Toxin Substrate 1, Phosphodiesterase 2, and Cell Membrane.
The key mechanisms of action in the Corneal Ulcers pipeline product include Phosphodiesterase 2 Inhibitor with one drug in Discovery. The Corneal Ulcers pipeline products include four routes of administration with the top ROA being Ophthalmic and three key molecule types in the Corneal Ulcers pipeline products market including Small Molecule, and Synthetic Peptide.
Corneal Ulcers overview
A corneal ulcer is a defect in the surface epithelium of the cornea that involves the underlying stroma. It is common in contact lens wearers and presents as eye pain, blurry vision, and photophobia. This is also called as Keratitis.
For a complete picture of Corneal Ulcers’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
